Masuo Yamaoka

Summary

Affiliation: Pharmaceutical Research Division
Country: Japan

Publications

  1. doi request reprint Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
    Masuo Yamaoka
    Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
    J Steroid Biochem Mol Biol 129:115-28. 2012
  2. doi request reprint Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer
    Masuo Yamaoka
    Takeda Pharmaceutical Company Limited, Tsukuba, Japan
    Clin Cancer Res 16:4319-24. 2010
  3. doi request reprint Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats
    Takahito Hara
    Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, Fujisawa, Japan
    J Steroid Biochem Mol Biol 134:80-91. 2013
  4. doi request reprint Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
    Tomohiro Kaku
    CNS Drug Discovery Unit, Takeda Pharmaceutical Company, Ltd, Shonan Research Center, 26 1, Muraoka Higashi 2 chome, Fujisawa, Kanagawa 251 0012, Japan
    Bioorg Med Chem 19:6383-99. 2011
  5. doi request reprint Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys
    Masuo Yamaoka
    Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa and Osaka, Japan Electronic address
    J Steroid Biochem Mol Biol 138:298-306. 2013
  6. doi request reprint Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1, Muraokahigashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 21:70-83. 2013
  7. doi request reprint Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1, Muraokahigashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 20:2338-52. 2012
  8. doi request reprint Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1 Muraokahigashi 2 chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 20:422-34. 2012
  9. doi request reprint A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line
    Takahito Hara
    Pharmacology Research Laboratories, Takeda Pharmaceutical Company Limited, Tsukuba, Japan
    Cell Biol Int 34:177-84. 2010
  10. ncbi request reprint C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors
    Nobuyuki Matsunaga
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division Takeda Chemical Industries Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 12:4313-36. 2004

Collaborators

  • Tomohiro Kaku
  • Masami Yamada
  • Takahito Hara
  • Satoshi Yamamoto
  • Masami Kusaka
  • Mitsuhiro Ito
  • Naoyuki Kanzaki
  • Akihiro Tasaka
  • Jin Kouno
  • Nobuyuki Matsunaga
  • Atsushi Hasuoka
  • Atsuo Baba
  • Hideo Araki
  • Kazuyo Nakamura
  • Katsuji Aikawa
  • Hiromi Kobayashi
  • Toshiyuki Takeuchi
  • Naoki Tomita
  • Shuichi Furuya
  • Yuri Suzuki
  • Tomohiko Suzaki
  • Kazumasa Hamamura
  • Takashi Santou
  • Takenori Hitaka
  • Junichi Miyazaki
  • Masahiko Hattori
  • Yukiko Hikichi
  • Kazutaka Ushio
  • Mayumi Nishiwaki
  • Yumi Imai
  • Toshimasa Tanaka
  • Akio Ojida

Detail Information

Publications12

  1. doi request reprint Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
    Masuo Yamaoka
    Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
    J Steroid Biochem Mol Biol 129:115-28. 2012
    ..These findings suggest that orteronel may be an effective therapeutic option for diseases where androgen suppression is critical, such as androgen sensitive and CRPC...
  2. doi request reprint Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer
    Masuo Yamaoka
    Takeda Pharmaceutical Company Limited, Tsukuba, Japan
    Clin Cancer Res 16:4319-24. 2010
    ..The study of circulating tumor cells will likely be important not only to identify patients likely to receive benefit from this therapeutic approach, but also to further understand the molecular mechanisms of resistance...
  3. doi request reprint Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats
    Takahito Hara
    Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, Fujisawa, Japan
    J Steroid Biochem Mol Biol 134:80-91. 2013
    ..Our data suggests that orteronel would therefore be effective for androgen-dependent disorders such as PC...
  4. doi request reprint Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
    Tomohiro Kaku
    CNS Drug Discovery Unit, Takeda Pharmaceutical Company, Ltd, Shonan Research Center, 26 1, Muraoka Higashi 2 chome, Fujisawa, Kanagawa 251 0012, Japan
    Bioorg Med Chem 19:6383-99. 2011
    ..Therefore, (+)-3c (termed orteronel [TAK-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer...
  5. doi request reprint Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys
    Masuo Yamaoka
    Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa and Osaka, Japan Electronic address
    J Steroid Biochem Mol Biol 138:298-306. 2013
    ....
  6. doi request reprint Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1, Muraokahigashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 21:70-83. 2013
    ..Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide...
  7. doi request reprint Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1, Muraokahigashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 20:2338-52. 2012
    ..These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model...
  8. doi request reprint Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists
    Satoshi Yamamoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26 1 Muraokahigashi 2 chome, Fujisawa, Kanagawa 251 8555, Japan
    Bioorg Med Chem 20:422-34. 2012
    ....
  9. doi request reprint A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line
    Takahito Hara
    Pharmacology Research Laboratories, Takeda Pharmaceutical Company Limited, Tsukuba, Japan
    Cell Biol Int 34:177-84. 2010
    ..These results suggest that an acquired mutation in beta-tubulin is associated with docetaxel resistance in PC and that a novel AR-targeted therapy is effective for docetaxel-resistant PC...
  10. ncbi request reprint C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors
    Nobuyuki Matsunaga
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division Takeda Chemical Industries Ltd, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 12:4313-36. 2004
    ..Furthermore, (S)-42 showed a potent suppression of testosterone biosynthesis after a single oral administration in monkeys. These data suggest that (S)-42 may be a promising agent for the treatment of androgen-dependent prostate cancer...
  11. ncbi request reprint Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline
    Takahito Hara
    Pharmacology Research Laboratories I, Takeda Chemical Industries, Ltd, Osaka 532 8686, Japan
    Cancer Res 63:5622-8. 2003
    ....
  12. ncbi request reprint Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells
    Takahito Hara
    Pharmacology Research Laboratories I, Takeda Pharmaceutical Company Limited, 17 85, Jusohonmachi 2 chome, Yodogawa ku, Osaka, Japan
    Prostate 65:268-75. 2005
    ..In this report, we examined one possible mechanism of the resistance...